A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2
To investigate the safety and efficacy of Nivolumab as a single agent or in combination with
Ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC),
pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and
ovarian cancer (OC). A combination of Nivolumab with Ipilimumab and Cobimetinib is also
investigated in PC.
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
Phase 1/Phase 2
The purpose of this study is to examine if Nivolumab alone, Nivolumab in combination with
Ipilimumab, or Nivolumab in combination with Ipilimumab and Cobimetinib will demonstrate a
meaningful objective response rate in patients with recurrent and metastatic colon cancer
who also have a specific biomarker in their tumors.
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
This is a multicenter, non-randomized, open-label study designed to evaluate four treatment
regimens in patients with advanced cancer for whom there is no available, beneficial
treatment. Patients with HER2 overexpression, amplification, or -activating mutation will be
treated with Herceptin/Perjeta; those with epidermal growth factor receptor (EGFR), with
Tarceva; those with BRAF-activating mutation, with Zelboraf/Cotellic; and those with Hedehog
pathway potentially clinically relevant mutation, with Erivedge. Treatment will continue
until disease progression or unacceptable toxicity occurs. Study is expected to last up to 5
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.